Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • RTM
    Junior Member
    • Oct 2013
    • 7

    #1

    Variant calling on matched primary and metastatic tumor without normal samples.

    Hello!

    I have exome sequencing data for 20 pairs of primary and matched metastatic tumors coming different patients. However, I have no Normal samples.

    I am interested in looking at mutation evolution from the primary to metastatic samples. What would be the best strategy to call variants? The way I see it, I have two options:

    1) Call variants using the primary sample as the control sample for their matched metastatic sample and use the metastatic sample as the normal for the primary sample.

    2) Follow the TCGA workflow for Tumor-Only variant calling and just call the samples independently. https://docs.gdc.cancer.gov/Data/Bio...ation-workflow

    3) Would it make more sense to create a "Panel of Normals" for each patient using the matched primary and metastatic tumor?

    I would like to hear your thoughts on how to approach this problem. thank you all in advance for the advice!!!

Latest Articles

Collapse

  • SEQadmin2
    16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
    by SEQadmin2




    NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
    Yesterday, 06:46 AM
  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-28-2026, 09:57 AM
0 responses
29 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-28-2026, 09:51 AM
0 responses
21 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
71 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
48 views
0 reactions
Last Post SEQadmin2  
Working...